Would you consider the use of PARP inhibitors in patients with BARD 1 mutation and refractory pancreatic cancer?
With extensive use of NGS testing, it is commonplace to identify mutations that have no validated therapeutic intervention, but strong biologic signal of potential benefit. What is your approach in such situations?
Community PollStarted
Would you use PARP inhibitors in patients with BARD 1 Mutation and refractory pancreatic cancer?
45 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Henry Ford Cancer Institute (HFCI)
Answered on
I will use it.
In a disease like pancreatic adenocarcinoma, where treatment options are so limited, one has a much lower threshold to think out of the box. Of course there is no good (or any) data on the use of PARPi in this particular setting. However, with the manageable toxicity of the PARPi, I wo...
Join for free or sign in to see the full answer